National Center on Minority Health and Health Disparities; Notice of Closed Meetings, 12766-12767 [2010-5540]

Download as PDF 12766 Federal Register / Vol. 75, No. 51 / Wednesday, March 17, 2010 / Notices May 2009 (HHS Reference No. E–191– 2009/0–US–01). Licensing Status: Available for licensing. Licensing Contact: Patrick P. McCue, PhD; 301–496–7057; mccuepat@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the pAkt assay for use in a clinical setting. The National Cancer Institute would be particularly interested in discussing collaborations to provide additional clinical validation of pAkt as a primary biomarker. Please contact John Hewes, PhD at 301–435– 3131 or hewesj@mail.nih.gov for more information. Dated: March 10, 2010. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2010–5765 Filed 3–16–10; 8:45 am] 756, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–7682, pateldg@niddk.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Translational Research. Date: May 20, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Michele L. Barnard, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 753, 6707 Democracy Boulevard, Bethesda, MD 20892–2542, (301) 594–8898, barnardm@extra.niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: March 10, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2010–5768 Filed 3–16–10; 8:45 am] BILLING CODE 4140–01–P National Institutes of Health Contact Person: Kenneth A. Roebuck, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5106, MSC 7852, Bethesda, MD 20892, (301) 435– 1166, roebuckk@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Ethical, Legal and Societal Implications of Genetic Information. Date: April 19, 2010. Time: 12 p.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call) Contact Person: Cheryl M. Corsaro, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2204, MSC 7890, Bethesda, MD 20892, (301) 435– 1045, corsaroc@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: March 10, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–5770 Filed 3–16–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1 National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings National Institutes of Health National Institutes of Health Center for Scientific Review; Notice of Closed Meetings National Center on Minority Health and Health Disparities; Notice of Closed Meetings Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; RO1 Review. Date: April 6, 2010. Time: 2 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892. (Telephone Conference Call) Contact Person: D.G. Patel, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room VerDate Nov<24>2008 15:08 Mar 16, 2010 Jkt 220001 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: AOIC & VACC. Date: April 7–8, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting) PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center on Minority Health and Health Disparities Special Emphasis Panel Loan Repayment Program for Health Disparities Research— Panel 2. Date: April 5, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\17MRN1.SGM 17MRN1 Federal Register / Vol. 75, No. 51 / Wednesday, March 17, 2010 / Notices Place: National Institutes of Health, Two Democracy Plaza 6707 Democracy Boulevard 800, Bethesda, MD 20892. (Virtual Meeting) Contact Person: Prabha L. Atreya, PhD, Chief, Office of Scientific Review, National Center on Minority Health and Health Disparities, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892, (301) 594– 8696, atreyapr@mail.nih.gov. Name of Committee: National Center on Minority Health and Health Disparities Special Emphasis Panel R13 Special Emphasis Panel Date: April 8, 2010. Time: 8 a.m. to 5 a.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6706 Democracy Blvd. 800, Bethesda, MD 20892. (Virtual Meeting) Contact Person: Prabha L. Atreya, PhD, Chief, Office of Scientific Review, National Center on Minority Health, and Health Disparities, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892, (301) 594– 8696, atreyaprmail.nih.gov. Name of Committee: National Center on Minority Health and Health Disparities Special Emphasis Panel Loan Repayment Program for Health Disparities Research— Panel 3. Date: April 19, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892. (Virtual Meeting) Contact Person: Prabha L. Atreya, PhD, Chief, Office Of Scientific Review, National Center On Minority Health and Health Disparities, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 20892, (301) 594– 8696, atreyapr/@mail.nih.gov. Dated: March 8, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–5540 Filed 3–16–10; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1 [Docket No. FDA–2010–N–0001] Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration VerDate Nov<24>2008 15:08 Mar 16, 2010 Jkt 220001 (FDA). The meeting will be open to the public. Name of Committees: Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. General Function of the Committees: To provide advice and recommendations to the agency on FDA’s regulatory issues. Date and Time: The meeting will be held on April 22, 2010, from 8 a.m. to 4:30 p.m. Location: Hilton Washington DC North/Gaithersburg, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD. The hotel phone number is 301–977–8900. Contact Person: Kalyani Bhatt, Center for Drug Evaluation and Research (HFD– 21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, FAX: 301– 827–6776, e-mail: Kalyani.Bhatt@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in Washington, DC area), codes 3014512529 and 3014512535. Please call the Information Line for up-to-date information on this meeting. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Web site and call the appropriate advisory committee hotline/ phone line to learn about possible modifications before coming to the meeting. Agenda: On April 22, 2010, the committees will discuss new drug application (NDA) 22–451 ACUROX (oxycodone HCl and niacin) Tablets, Acura Pharmaceuticals, Inc., for the proposed indication of relief of moderate to severe pain where the use of an immediate-release, orally administered, opioid analgesic tablet is appropriate, and the results of studies evaluating the addition of niacin, added for the purpose of reducing the misuse of oxycodone. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at https://www.fda.gov/ AdvisoryCommittees/Calendar/ PO 00000 Frm 00045 Fmt 4703 Sfmt 9990 12767 default.htm. Scroll down to the appropriate advisory committee link. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before April 15, 2010. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before April 7, 2010. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by April 8, 2010. Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Kalyani Bhatt at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at https://www.fda.gov/ AdvisoryCommittees/AboutAdvisory Committees/ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: March 11, 2010. Jill Hartzler Warner, Acting Associate Commissioner for Special Medical Programs. [FR Doc. 2010–5815 Filed 3–16–10; 8:45 am] BILLING CODE 4160–01–S E:\FR\FM\17MRN1.SGM 17MRN1

Agencies

[Federal Register Volume 75, Number 51 (Wednesday, March 17, 2010)]
[Notices]
[Pages 12766-12767]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-5540]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center on Minority Health and Health Disparities; Notice 
of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center on Minority Health and Health 
Disparities Special Emphasis Panel Loan Repayment Program for Health 
Disparities Research--Panel 2.
    Date: April 5, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.

[[Page 12767]]

    Place: National Institutes of Health, Two Democracy Plaza 6707 
Democracy Boulevard 800, Bethesda, MD 20892. (Virtual Meeting)
    Contact Person: Prabha L. Atreya, PhD, Chief, Office of 
Scientific Review, National Center on Minority Health and Health 
Disparities, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 
20892, (301) 594-8696, atreyapr@mail.nih.gov.

    Name of Committee: National Center on Minority Health and Health 
Disparities Special Emphasis Panel R13 Special Emphasis Panel
    Date: April 8, 2010.
    Time: 8 a.m. to 5 a.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6706 Democracy Blvd. 800, 
Bethesda, MD 20892. (Virtual Meeting)
    Contact Person: Prabha L. Atreya, PhD, Chief, Office of 
Scientific Review, National Center on Minority Health, and Health 
Disparities, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 
20892, (301) 594-8696, atreyaprmail.nih.gov.

    Name of Committee: National Center on Minority Health and Health 
Disparities Special Emphasis Panel Loan Repayment Program for Health 
Disparities Research--Panel 3.
    Date: April 19, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Suite 800, Bethesda, MD 20892. (Virtual 
Meeting)
    Contact Person: Prabha L. Atreya, PhD, Chief, Office Of 
Scientific Review, National Center On Minority Health and Health 
Disparities, 6707 Democracy Boulevard, Suite 800, Bethesda, MD 
20892, (301) 594-8696, atreyapr/@mail.nih.gov.


    Dated: March 8, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-5540 Filed 3-16-10; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.